Advanced Pancreatic Cancer Successfully Treated with Biweekly Low-Dose Gemcitabine

A 74-year-old male was admitted to our hospital in August 2006 because of an exacerbation of the symptom of diabetes mellitus. Abdominal CT showed locally advanced cancer of the head of the pancreas with encasement of the superior mesenteric artery, suggesting that the lesion was unresectable. The p...

Full description

Saved in:
Bibliographic Details
Published in:Annals of Cancer Research and Therapy 2008, Vol.16(1), pp.21-22
Main Authors: Kishikawa, Hiroshi, Nishida, Jiro, Inokuchi, Sayaka, Kaida, Shogo, Morishita, Tetsuo, Hibi, Toshifumi
Format: Article
Language:English
Subjects:
biweekly administration
gemcitabine
pancreatic cancer
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 74-year-old male was admitted to our hospital in August 2006 because of an exacerbation of the symptom of diabetes mellitus. Abdominal CT showed locally advanced cancer of the head of the pancreas with encasement of the superior mesenteric artery, suggesting that the lesion was unresectable. The patient was scheduled for treatment with gemcitabine at the standard dose of 1000 mg/m2 once a week for 3 consecutive weeks followed by a one week rest, but on day 7 of cycle 1, grade 3 of hematological toxicity was diagnosed, and the schedule was changed to biweekly administration at a dose of 1000 mg/m2. The biweekly low-dose gemcitabine regimen slightly reduced tumor size, and the regimen was continued for 12 months. This case suggests that this new biweekly regimen of gemcitabine can be used as a safe and effective first-line chemotherapy for patients with advanced pancreatic cancer who are unable to tolerate the standard regimen of gemcitabine.
ISSN:1344-6835
1880-5469
DOI:10.4993/acrt.16.21